Gastric Cancer Clinical Trial
Official title:
Changes in Lipid Indices and Body Composition One Year After Laparoscopic Gastrectomy: a Prospective Study
Nutritional status including changes of body composition is one of the most important
clinical determinants of outcome after gastrectomy for gastric cancer. Various type of
gastric operations are widely used with favorable outcome in South Korea. It was reported
that several advantages of laparoscopic gastrectomy are the prevention of overt weight loss
and enhanced recovery of muscle mass at 6 months after surgery. But there have been no
longitudinal studies evaluating changes in the body composition according to the different
type of anastomosis of laparoscopic gastrectomy.
The purpose of this prospective study was to investigate changes in lipid indices associated
with whole body composition during 1 year of follow-up after laparoscopic gastrectomy.
Gastrectomy resulted in improved lipid indices and a reduction in body weight, fat and LBM.
The HDL-Csignificantly increased in the non-obese group for 1 year after gastrectomy and the
reduction of TG level was positively correlated with fat, especially with trunk fat.
- All patients will undergo a laparoscopic gastrectomy for their gastric cancer (proved to
be stage I or II) or benign gastric neoplasm by preoperative screening diagnostic
procedure. They will receive laparoscopic gastrectomy as follows: (1) wedge resection,
subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection;
(3) laparoscopic gastrectomy; (4 gastroduodenal anastomosis or duodenal bypass,
including Roux-en-Y or gastrojejunostomy.
- Pre-operative, 6 and 12 months post-operative body composition measurement will be
performed on each patient. The whole body composition measurement will be assessed by
Hologic 4500/A dual energy X-ray absorptiometry system. The software performs
calculations of the differential attenuations of the two photon energies and present
data of percentage of fat, fat mass (g), lean mass (g), bone mineral content (g), bone
mineral density (g/cm2), and total mass (g).
- Laboratory analysis - There is a battery of labs that are ordered in both the
pre-operative, 6 and 12 months post-operative time frame. These labs are ordered
independent of the patient's participation in the study. These labs are ordered to
evaluate and to assist management of the patient's medical comorbidities as well as to
assess for adequate nutritional intake and balance.
- Queries on nutritional intake and exercise will be made at each post-operative
appointment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |